Initiated Buy X

LNTH Lantheus Holdings

Redburn Atlantic

$175

Reiterated Mkt Outperform X

LNTH Lantheus Holdings

JMP Securities

$100 $130

Downgrades Outperform Mkt Perform X

LNTH Lantheus Holdings

William Blair

Initiated Outperform X

LNTH Lantheus Holdings

TD Cowen

$100

Initiated Outperform X

LNTH Lantheus Holdings

William Blair

Initiated Mkt Outperform X

LNTH Lantheus Holdings

JMP Securities

$120

Initiated Outperform X

LNTH Lantheus Holdings

SVB Leerink

Initiated Buy X

LNTH Lantheus Holdings

Mizuho

$105

Initiated Buy X

LNTH Lantheus Holdings

B. Riley Securities

$91

Initiated Buy X

LNTH Lantheus Holdings

Truist

$77

Initiated Outperform X

LNTH Lantheus Holdings

SVB Leerink

$24

Upgrades Mkt Perform Mkt Outperform X

LNTH Lantheus Holdings

CJS Securities

LNTH  Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: US Segment and International Segment. The US Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.